(Q84273556)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21640925%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

Novel developments in IBD-related sclerosing cholangitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21640925%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

main subject

sclerosing cholangitis

1 reference

C Y Ponsioen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21640925%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21640925%20AND%20SRC:MED&resulttype=core&format=json

Best Practice and Research: Clinical Gastroenterology

3 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21640925%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

25 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21640925%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

S15-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21640925%20AND%20SRC:MED&resulttype=core&format=json

Hepatic and extrahepatic malignancies in primary sclerosing cholangitis

3 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

Cholestatic liver diseases and health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

Cholangiocarcinoma complicating primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

Bile acids for primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

Novel biotransformation and physiological properties of norursodeoxycholic acid in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

Immunohistochemical analysis of inflammation in primary sclerosing cholangitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease)

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

Natalizumab for induction of remission in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2811%2970005-1

7 January 2021

10.1016/S1521-6918(11)70005-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21640925%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference